Truveta Studio delivers the health data and analytics the world deserves now
November 02, 2022 09:00 ET
|
Truveta
BELLEVUE, Wash., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Today, Truveta announced the availability of Truveta Studio, bringing together unprecedented health data and analytics for researchers to study...
Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions
September 28, 2022 07:12 ET
|
Resverlogix Corp
CALGARY, Alberta, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) today announced that apabetalone’s future clinical development related to COVID-19...
The ¡Ándale! ¿Qué Esperas? Campaign Partners with Grupo Chespirito to Bring El Chavo Animado Vaccination Message to Parents & Children
April 05, 2022 10:00 ET
|
AltaMed
Los Angeles, April 05, 2022 (GLOBE NEWSWIRE) -- The ¡Ándale! ¿Qué Esperas? campaign by AltaMed Health Services partnered with Grupo Chespirito to produce a PSA featuring the iconic characters of...
Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada
February 17, 2022 07:12 ET
|
Resverlogix Corp
CALGARY, Alberta, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced that the first Brazilian site has been initiated for its Phase 2b study to evaluate...
Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment
January 18, 2022 07:15 ET
|
Resverlogix Corp
CALGARY, Alberta, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today that enrollment and dosing of patients has commenced in a Phase 2b study...
Molecular Partners and Novartis Report Positive Topline Data from Phase 2 Study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19
January 10, 2022 01:17 ET
|
Molecular Partners
Topline results from the randomized, placebo-controlled EMPATHY Part A study in acute COVID-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic...
Dignitaries from Prez. Biden’s Administration & Others Visited Sunrise Group of Companies
November 22, 2021 14:36 ET
|
Sunrise Group of Companies
South Plainfield, New Jersey, Nov. 22, 2021 (GLOBE NEWSWIRE) -- MR.Mohammad Naeem(Founder and Chairman SGoS) with MR. Jim McGreevey (Former Governor Of New Jersey) 22nd November 2021, New...
Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-African Economy to Support the Development of Apabetalone for COVID-19 Patients
November 03, 2021 08:00 ET
|
Resverlogix Corp
CALGARY, Alberta, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the Company”) (TSX: RVX), a world leader in epigenetics or gene regulation, is pleased to announce today that...
Resverlogix In Active Discussions With The Kingdom of Morocco’s Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Drug Apabetalone
November 01, 2021 08:30 ET
|
Resverlogix Corp
CALGARY, Alberta, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX), a world leader in epigenetics or gene regulation, is pleased to announce today...
Resverlogix to Present at Upcoming Conferences
October 13, 2021 08:00 ET
|
Resverlogix Corp
CALGARY, Alberta, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the Company”) (TSX: RVX), a world leader in epigenetics or gene regulation, announces today that President and...